<code id='E023D6CBCF'></code><style id='E023D6CBCF'></style>
    • <acronym id='E023D6CBCF'></acronym>
      <center id='E023D6CBCF'><center id='E023D6CBCF'><tfoot id='E023D6CBCF'></tfoot></center><abbr id='E023D6CBCF'><dir id='E023D6CBCF'><tfoot id='E023D6CBCF'></tfoot><noframes id='E023D6CBCF'>

    • <optgroup id='E023D6CBCF'><strike id='E023D6CBCF'><sup id='E023D6CBCF'></sup></strike><code id='E023D6CBCF'></code></optgroup>
        1. <b id='E023D6CBCF'><label id='E023D6CBCF'><select id='E023D6CBCF'><dt id='E023D6CBCF'><span id='E023D6CBCF'></span></dt></select></label></b><u id='E023D6CBCF'></u>
          <i id='E023D6CBCF'><strike id='E023D6CBCF'><tt id='E023D6CBCF'><pre id='E023D6CBCF'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:82
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Time to name cancers by genetics, not organ of origin, expert says
          Time to name cancers by genetics, not organ of origin, expert says

          Treatmentsforlungcancercanvarydependingonspecificmutation.Anoncologistarguesthecancersshouldhavediff

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          What we need to know about Arena Bioworks

          AdobeI’vespentagooddealofmycareerthinkingabouthowwestructureandfundresearchinthebiomedicalsciencesin